SALT LAKE CITY 鈥 Norman Foster was drawn to Alzheimer鈥檚 disease by its intellectual challenge, its increasing importance as a medical problem, and perhaps most by the life-changing affect Alzheimer鈥檚 disease has on patients and families. 鈥淚t is personally rewarding to make a difference by providing optimal care and support for patients with dementia and their families,鈥 Foster says.
This Saturday, March 6, Foster, who established the University of Utah鈥檚 Center for Alzheimer鈥檚 Care, Imaging, and Research, will be honored for his pioneering research and clinical innovations when he receives the ALEXA Award from the Utah Chapter of the Alzheimer鈥檚 Association. The award is given to an individual who exemplifies a lifetime of achievement in understanding and treating Alzheimer鈥檚 disease. 鈥淲orking with Dr Norman Foster has been a pleasure for me personally as well as for the Alzheimer鈥檚 Association as a whole. He is a consummate professional who carries many responsibilities but has always made time to collaborate closely with the Alzheimer鈥檚 Association Utah Chapter, and we are all better for it,鈥 says Jack Jenks, Executive Director of the Utah Chapter.
Dr. Foster joined the University of Utah in 2005 as professor in the Department of Neurology, Director of the Center for Alzheimer's Care, Imaging and Research (CACIR), and Senior Investigator for the Brain Institute. He is also a member of the Utah Commission on Aging, and part of the steering committee for the University of Utah Center on Aging.
Dr. Foster completed his undergraduate training at MacMurray College in Illinois, graduating summa cum laude with a dual major in biology and chemistry. He received his M.D. from the Washington University School of Medicine in St. Louis, where he subsequently completed his internship. After completing his residency in neurology at the University of Utah in Salt Lake City, Dr. Foster relocated to Bethesda, Maryland for a three-year fellowship in experimental therapeutics with the National Institute of Neurological and Communicative Disorders and Stroke (NINDS) at the NIH.
Before returning to Utah, Dr. Foster spent more than 20 years in the faculty of the Department of Neurology at the University of Michigan. While there, he developed the first clinical program for the diagnosis and treatment of dementing disorders in the state of Michigan. This formed the nucleus of the Clinical Core of the NIH-funded Michigan Alzheimer鈥檚 Disease Research Center (ADRC), which Dr. Foster helped direct for the first 16 years of its funding from 1989 to 2005.
鈥淭he University of Utah Department of Neurology is lucky to have a researcher and clinician of Dr. Foster鈥檚 stature. His concern for patients with dementia and his drive to better understand this disease is inspiring to all who work with him,鈥 says Stefan-M. Pulst, chair of the Department of Neurology. 鈥淲e are thrilled that his work is being recognized with the ALEXA award.鈥
As the U.S. population ages, dementia care has become one of the nation鈥檚 most pressing health care needs. In addition, the strain on families and caregivers is considerable. 鈥淎s a society we need to make a commitment to improve the quality of care for patients with Alzheimer鈥檚 disease. Patients and their families deserve it,鈥 says Foster. Under his direction, the Center for Alzheimer鈥檚 Care, Imaging, and Research has implemented the Proactive Dementia Care Model, which educates caregivers and families about dementia and the choices that lay ahead when a family member or loved one is diagnosed. This model provides better support for caregivers and family members, patients鈥 primary care physicians, and frees up CACIR staff to see and diagnose more patients.
鈥淭here is enormous reason for hope,鈥 says Foster. 鈥淩esearch has taught us a great deal: We have ways to identify Alzheimer鈥檚 disease before dementia develops and can accurately track the course of the disease. We know basic things that can decrease and individual鈥檚 risk of dementia and we have some proven drug treatments.鈥
鈥淲hile we still need more effective drugs,鈥 Foster continues, 鈥渨e now better understand what patients and families need to successfully manage this disease. Much more needs to be done, but the way to finding a cure is now in sight. With enough patients and families participating in research, enough investigators conducting the studies and sufficient funding, we will find a way.鈥